SELLAS Life Sciences Announces Inclusion in Russell Microcap® Index
SELLAS Life Sciences Group (Nasdaq: SLS) announced its inclusion in the Russell Microcap Index, effective June 28, 2021. This inclusion is a significant milestone expected to enhance the company's visibility within the investment community. SELLAS, known for developing cancer immunotherapies, notably its lead candidate GPS, aims to provide treatment options for various cancer types. The Russell Microcap Index inclusion lasts for a year and is determined by market capitalization and style attributes, impacting approximately $10.6 trillion in assets.
- Inclusion in the Russell Microcap Index is anticipated to increase company visibility and attract potential investments.
- SELLAS is actively developing cancer immunotherapies with the potential to treat various malignancies.
- Potential risks include uncertainties related to clinical development and regulatory approvals for their products.
NEW YORK, June 22, 2021 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (Nasdaq: SLS) ("SELLAS" or the “Company”), a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies for a broad range of indications, today announced that the Company will be included in the Russell Microcap® Index effective after the U.S. market opens on Monday, June 28, 2021, as based on the preliminary list of additions.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately
“Inclusion in the Russell Microcap® Index represents another important milestone for SELLAS and is an achievement that will undoubtedly increase awareness and visibility of our company within the investment community,” said Angelos Stergiou, MD, ScD hc, President and Chief Executive Officer, SELLAS. “Our inclusion is a testament to our diligent work on our clinical development programs for our lead asset, galinpepimut-S (GPS) which have the potential to result in a treatment for multiple cancer indications that will help patients to stay in remission and live longer. We look forward to sharing the SELLAS story as well as updates on our execution and milestones, which are currently on track, with a wider investor audience as part of the FTSE Russell Microcap® Index.”
Membership in the Russell Microcap® Index, which remains in place for one year, means automatic inclusion in the appropriate growth and value style indexes. FTSE Russell determines membership for its Russell indexes primarily by objective market-capitalization rankings and style attributes.
For more information on the Russell Microcap® Index and the Russell indexes reconstitution, go to the "Russell Reconstitution" section on the FTSE Russell website.
About FTSE Russell:
FTSE Russell is a global index leader that provides innovative benchmarking, analytics and data solutions for investors worldwide. FTSE Russell calculates thousands of indexes that measure and benchmark markets and asset classes in more than 70 countries, covering
FTSE Russell index expertise and products are used extensively by institutional and retail investors globally. Approximately
A core set of universal principles guides FTSE Russell index design and management: a transparent rules-based methodology is informed by independent committees of leading market participants. FTSE Russell is focused on applying the highest industry standards in index design and governance and embraces the IOSCO Principles. FTSE Russell is also focused on index innovation and customer partnerships as it seeks to enhance the breadth, depth and reach of its offering.
FTSE Russell is wholly owned by London Stock Exchange Group.
About SELLAS Life Sciences Group, Inc.
SELLAS is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapeutics for a broad range of indications. SELLAS’ lead product candidate, GPS, is licensed from Memorial Sloan Kettering Cancer Center and targets the WT1 protein, which is present in an array of tumor types. GPS has potential both as a monotherapy and in combination to address a broad spectrum of hematologic malignancies and solid tumor indications. SELLAS’ second product candidate, nelipepimut-S (NPS), is a HER2-directed cancer immunotherapy with potential to treat patients with early-stage breast cancer with low to intermediate HER2 expression, otherwise known as HER2 1+ or 2+, which includes triple negative breast cancer patients, following the standard of care.
For more information on SELLAS, please visit www.sellaslifesciences.com.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts are “forward-looking statements,” including those relating to future events. In some cases, forward-looking statements can be identified by terminology such as “plan,” “expect,” “anticipate,” “may,” “might,” “will,” “should,” “project,” “believe,” “estimate,” “predict,” “potential,” “intend,” or “continue” and other words or terms of similar meaning. These statements include, without limitation, statements related to the inclusion in the Russell Microcap Index.. These forward-looking statements are based on current plans, objectives, estimates, expectations and intentions, and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the COVID-19 pandemic and its impact on the Company’s clinical plans, risks and uncertainties associated with immune-oncology product development and clinical success thereof, the uncertainty of regulatory approval, and other risks and uncertainties affecting SELLAS and its development programs as set forth under the caption “Risk Factors” in SELLAS’ Annual Report on Form 10-K filed on March 23, 2021 and in its other SEC filings. Other risks and uncertainties of which SELLAS is not currently aware may also affect SELLAS’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof. SELLAS undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.
For more information, please contact:
Investor Contacts
Valter Pinto / Allison Soss
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 914.907.2675 / 215.272.2707
Media Contacts
Caitlin Kasunich / Raquel Cona
KCSA Strategic Communications
Email: SELLAS@kcsa.com
Phone: 212.896.1241 / 212.896.1276
FAQ
What is the significance of SELLAS Life Sciences being included in the Russell Microcap Index?
When does SELLAS Life Sciences officially join the Russell Microcap Index?
What is the ticker symbol for SELLAS Life Sciences?
What type of therapies does SELLAS Life Sciences develop?
What is SELLAS's lead product candidate?
